Publications in collaboration with researchers from Harvard Medical School (9)

2023

  1. Ambulatory cancer patients: who should definitely receive antithrombotic prophylaxis and who should never receive

    Internal and Emergency Medicine, Vol. 18, Núm. 6, pp. 1619-1634

  2. Risk factors for recurrence and major bleeding in patients with cancer-associated venous thromboembolism

    European Journal of Internal Medicine, Vol. 112, pp. 29-36

2022

  1. 2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19

    The Lancet Oncology, Vol. 23, Núm. 7, pp. e334-e347

  2. Apixaban and Dalteparin for the Treatment of Venous Thromboembolism in Patients with Different Sites of Cancer

    Thrombosis and Haemostasis, Vol. 122, Núm. 5, pp. 796-807

  3. Recurrent venous thromboembolism and major bleeding in patients with localised, locally advanced or metastatic cancer: an analysis of the Caravaggio study

    European Journal of Cancer, Vol. 165, pp. 136-145

2021

  1. Motixafortide and pembrolizumab combined to nanoliposomal irinotecan, fluorouracil, and folinic acid in metastatic pancreatic cancer: The COMBAT/ KEYNOTE-202 trial

    Clinical Cancer Research, Vol. 27, Núm. 18, pp. 5020-5027

2020

  1. Apixaban for the treatment of venous thromboembolism associated with cancer

    New England Journal of Medicine, Vol. 382, Núm. 17, pp. 1599-1607

  2. BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial

    Nature Medicine, Vol. 26, Núm. 6, pp. 878-885

2018

  1. Management of hyperbilirubinaemia in pancreatic cancer patients

    European Journal of Cancer, Vol. 94, pp. 26-36